<DOC DOCNO="nw/wsj/00/wsj_0023@0023@wsj@nw@en@on">
<ENAMEX TYPE="ORG">F.H. Faulding -AMP- Co.</ENAMEX> , an <ENAMEX TYPE="NORP">Australian</ENAMEX> pharmaceuticals company , said its <ENAMEX TYPE="ORG">Moleculon Inc.</ENAMEX> affiliate acquired <ENAMEX TYPE="ORG">Kalipharma Inc.</ENAMEX> for <ENAMEX TYPE="MONEY">$ 23 million</ENAMEX> .
<ENAMEX TYPE="ORG">Kalipharma</ENAMEX> is a <ENAMEX TYPE="GPE">New Jersey</ENAMEX> - based pharmaceuticals concern that sells products under the <ENAMEX TYPE="PRODUCT">Purepac</ENAMEX> label .
<ENAMEX TYPE="ORG">Faulding</ENAMEX> said it owns <ENAMEX TYPE="PERCENT">33 %</ENAMEX> of <ENAMEX TYPE="ORG">Moleculon</ENAMEX> 's voting stock and has an agreement to acquire <ENAMEX TYPE="PERCENT">an additional 19 %</ENAMEX> .
That stake , together with its convertible preferred stock holdings , gives <ENAMEX TYPE="ORG">Faulding</ENAMEX> the right to increase its interest to <ENAMEX TYPE="PERCENT">70 %</ENAMEX> of <ENAMEX TYPE="ORG">Moleculon</ENAMEX> 's voting stock .
</DOC>
